Kanazawa Blood Test Detects 90% of Earliest Pancreatic Cancers, Beating CA19-9's 10%
Updated
Updated · Newsweek · Jul 17
Kanazawa Blood Test Detects 90% of Earliest Pancreatic Cancers, Beating CA19-9's 10%
3 articles · Updated · Newsweek · Jul 17
Summary
A 56-gene blood expression panel identified 9 of 10 stage 0 or stage I pancreatic cancers in a Kanazawa University study, targeting a disease usually found only after symptoms appear.
The test reads gene activity in circulating immune cells rather than the tumor itself, based on evidence that even small pancreatic tumors alter those cells' behavior.
CA19-9 alone detected just 1 of 10 early cancers, while the combined Panregza test reached 60% sensitivity with 93.3% specificity against 104 healthy volunteers.
Pancreatic cancer's five-year survival rate is 13% globally and 8.5% in Japan, while only 2% to 3% of cases are caught early enough for potentially curative surgery.
Researchers and outside specialists called the findings promising but stressed the single-center pilot needs validation in larger, more diverse populations before wider screening use.
A new test catches 90% of early pancreatic cancers, but could its high false alarm rate create a bigger medical problem?
This Japanese test seems revolutionary, but will rival AI-powered scans or other blood tests actually reach patients first?
Breakthrough in Pancreatic Cancer: Panregza Test Achieves 90% Sensitivity for Stage 0–I Detection
Overview
A research team at Kanazawa University developed the Panregza test, marking a major step forward in the early detection of pancreatic cancer. By using a 56-gene expression panel from peripheral whole blood, Panregza can identify subtle molecular changes linked to early-stage cancer. This approach is based on the discovery that gene expression patterns in immune cells differ between healthy people and those with pancreatic cancer, even when the tumor is very small. Early detection with Panregza can lead to better patient outcomes and higher survival rates, offering new hope against this challenging disease.